Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 76Neoplasms 16Prostatic Neoplasms, Castration-Resistant 14Neoplasm Metastasis 9Breast Neoplasms 9Metastatic Castration Resistant Prostate Cancer 8Prostate Cancer Metastatic 5Metastatic Castration-Resistant Prostate Cancer 5Colorectal Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Metastatic Castration-resistant Prostate Cancer 3Melanoma 3Bulbo-Spinal Atrophy, X-Linked 3mCRPC 2Recurrence 2Pancreatic Neoplasms 2Non-metastatic Castration-resistant Prostate Cancer 2Metastatic Hormone-sensitive Prostate Cancer 2Metastatic Hormone Sensitive Prostate Cancer 2Metastatic Castrate-Resistant Prostate Cancer 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Bites and Stings 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumours 1Seizures 1

Interventions

enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × MCRPC × enzalutamide × Clear all
NCT03851640 2025-03-12

A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Hinova Pharmaceuticals Inc.

Phase 3 Recruiting
417 enrolled

MCRPC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡